<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yang X</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NINDS NIH HHS</funding><pagination>762-777.e9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11209835</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(4)</volume><pubmed_abstract>Although the role of ferroptosis in killing tumor cells is well established, recent studies indicate that ferroptosis inducers also sabotage anti-tumor immunity by killing neutrophils and thus unexpectedly stimulate tumor growth, raising a serious issue about whether ferroptosis effectively suppresses tumor development in vivo. Through genome-wide CRISPR-Cas9 screenings, we discover a pleckstrin homology-like domain family A member 2 (PHLDA2)-mediated ferroptosis pathway that is neither ACSL4-dependent nor requires common ferroptosis inducers. PHLDA2-mediated ferroptosis acts through the peroxidation of phosphatidic acid (PA) upon high levels of reactive oxygen species (ROS). ROS-induced ferroptosis is critical for tumor growth in the absence of common ferroptosis inducers; strikingly, los</pubmed_abstract><journal>Cell metabolism</journal><pubmed_title>PHLDA2-mediated phosphatidic acid peroxidation triggers a distinct ferroptotic response during tumor suppression.</pubmed_title><pmcid>PMC11209835</pmcid><funding_grant_id>R01 CA258390</funding_grant_id><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>R01 CA243142</funding_grant_id><funding_grant_id>R37 NS061817</funding_grant_id><funding_grant_id>R01 CA266342</funding_grant_id><funding_grant_id>R01 CA166413</funding_grant_id><funding_grant_id>R35 CA209896</funding_grant_id><funding_grant_id>R01 CA258622</funding_grant_id><funding_grant_id>P30 CA013696</funding_grant_id><funding_grant_id>R01 CA204232</funding_grant_id><funding_grant_id>R01 CA165065</funding_grant_id><funding_grant_id>R01 CA254970</funding_grant_id><funding_grant_id>U01 AI156923</funding_grant_id><funding_grant_id>U01 AI156924</funding_grant_id><funding_grant_id>R01 NS076511</funding_grant_id><funding_grant_id>R01 NS061817</funding_grant_id><funding_grant_id>R35 CA253059</funding_grant_id><pubmed_authors>Stockwell BR</pubmed_authors><pubmed_authors>Gu W</pubmed_authors><pubmed_authors>Kon N</pubmed_authors><pubmed_authors>Chen D</pubmed_authors><pubmed_authors>Tycko B</pubmed_authors><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Bayir H</pubmed_authors><pubmed_authors>Kagan VE</pubmed_authors><pubmed_authors>Kapralov AA</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Jiang X</pubmed_authors><pubmed_authors>Amoscato AA</pubmed_authors><pubmed_authors>Duan S</pubmed_authors><pubmed_authors>Tyurin VA</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Samovich SN</pubmed_authors><pubmed_authors>Dar HH</pubmed_authors></additional><is_claimable>false</is_claimable><name>PHLDA2-mediated phosphatidic acid peroxidation triggers a distinct ferroptotic response during tumor suppression.</name><description>Although the role of ferroptosis in killing tumor cells is well established, recent studies indicate that ferroptosis inducers also sabotage anti-tumor immunity by killing neutrophils and thus unexpectedly stimulate tumor growth, raising a serious issue about whether ferroptosis effectively suppresses tumor development in vivo. Through genome-wide CRISPR-Cas9 screenings, we discover a pleckstrin homology-like domain family A member 2 (PHLDA2)-mediated ferroptosis pathway that is neither ACSL4-dependent nor requires common ferroptosis inducers. PHLDA2-mediated ferroptosis acts through the peroxidation of phosphatidic acid (PA) upon high levels of reactive oxygen species (ROS). ROS-induced ferroptosis is critical for tumor growth in the absence of common ferroptosis inducers; strikingly, los</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-05-29T10:04:40.328Z</modification><creation>2025-04-07T02:10:30.589Z</creation></dates><accession>S-EPMC11209835</accession><cross_references><pubmed>38309267</pubmed><doi>10.1016/j.cmet.2024.01.006</doi></cross_references></HashMap>